Effect of Paroxetine on COAT-Platelet Production in Normal Volunteers and Patients With Cardiovascular Disease

Completed · Phase 4

Conditions studied: Coronary Artery Disease

In brief

COAT-platelets stands for collagen and thrombin stimulated platelets, which are two things in the body that make platelets stick together. These platelets may be important in the initiation of a heart attack (myocardial infarction). A chemical in the body called serotonin maybe responsible for COAT-platelet production. Paroxetine causes a significant reduction in platelet serotonin and therefore may have value in preventing heart attacks. Therefore, the current study is designed to determine whether paroxetine will decrease COAT-platelet production in normal volunteers and patients with cardiovascular disease.

Key facts

Study ID

NCT00229528

Run by

University of Oklahoma

People needed

25

Starts

2004-03-01

Expected to finish

2006-05-01

Last updated by the study team

2008-09-22

Who can join

Age: 18 and older, up to 65. Sex: any. Healthy volunteers: accepted.

You may qualify if…

• normal volunteers (without heart disease)
• patients with heart disease
• between ages 18 \& 65

You may not qualify if…

• children less than 18 years
• adults greater than 65 years
• those who can not keep appointments
• patients within 2 weeks of a coronary catheterization
• patients within 6 months of unstable angina or myocardial infarction
• individuals with allergies to paroxetine or similar medications
• individuals having adverse events to paroxetine or similar medications
• individuals with diagnosis of mania
• individuals with a diagnosis of hypomania
• individuals with a diagnosis of bipolar disorders
• individuals with a diagnosis of depression
• individuals with a diagnosis of panic disorders
• individuals with a diagnosis of seizure disorders
• individuals with a history of suicide attempts
• individuals with a diagnosis of hyponatremia
• individuals with active bleeding disorders
• individuals with a diagnosis of narrow angle glaucoma
• individuals with an estimated creatinine clearance of less that 30 ml/min
• individuals taking potentially interacting medications

Where it is running

• The University of Oklahoma Health Sciences Center — Oklahoma City, Oklahoma, United States

Full record on ClinicalTrials.gov

Trial information comes from ClinicalTrials.gov and is refreshed daily. TrialsForMe does not provide medical care and does not run the studies it lists.